Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Dis Markers ; 2017: 3510984, 2017.
Article in English | MEDLINE | ID: mdl-28348450

ABSTRACT

Exposure to asbestos is the main cause of malignant pleural mesothelioma (MPM), a highly aggressive cancer of the pleura. Since the only tools for early detection are based on radiological tests, some authors focused on serum markers (i.e., mesothelin). The aim of this study was the evaluation of new serum biomarkers to be used individually or in combination, in order to improve the outcome of patients whose disease would be diagnosed at an earlier stage. Serum and plasma were available from 43 subjects previously exposed to asbestos and 27 MPM patients, all being epithelioid type. All the new markers found differentially expressed in MPM and healthy subjects, by proteomic and genomic approaches, have been validated in the serum by the use of specific ELISA. The combined approach, using tools of genomics and proteomics, is found to be highly innovative for this type of disease and led to the identification of new serum markers in the diagnosis of MPM. These results, if confirmed in a larger series, may have a strong impact in this area, because early detection of this cancer in people at high risk could significantly improve the course of the disease and the clinical approach to an individualized therapy.


Subject(s)
Biomarkers, Tumor/blood , Lung Neoplasms/blood , Mesothelioma/blood , Aged , Blood Proteins/metabolism , Case-Control Studies , Female , Humans , Male , Mesothelioma, Malignant , Middle Aged , Proteome/metabolism
2.
Equine Vet J ; 48(1): 72-7, 2016 Jan.
Article in English | MEDLINE | ID: mdl-25290989

ABSTRACT

REASONS FOR PERFORMING STUDY: Convincing evidence shows that persistent or excessive expression of osteopontin (OPN) is linked to fibroproliferation of various organs in laboratory animals and in man, such that its downregulation is a logical therapeutic objective. OBJECTIVES: To investigate OPN expression in an equine model of wound healing and in clinical specimens of equine exuberant granulation tissue and human keloids in an effort to better understand the contribution of this protein to inflammation-associated skin fibrosis. STUDY DESIGN: Description of gene and protein expression in an experimental equine model of wound healing and clinical specimens in horse and man. METHODS: Osteopontin gene expression was evaluated by quantitative PCR, while protein expression was investigated by means of immunohistochemical staining. RESULTS: Quantitative PCR showed that the OPN gene is expressed in normal intact skin of horses and continues to be expressed during the wound-healing process. An increase in gene expression was observed throughout the phases of wound healing, with a final decrease at wound closure. The protein was not detected in normal skin. Keratinocytes in wound-edge samples did not express the protein, whereas dermal immunoreactivity was confined to inflammatory cells. Healed wounds were devoid of staining. Equine exuberant granulation tissue showed immunoreactivity of the surrounding epidermis, infiltrating neutrophils, mononuclear cells, endothelial cells and fibroblasts. Human keloids showed OPN immunoreactivity throughout the epidermis as well as in mononuclear cells and scattered fibroblasts. CONCLUSIONS: Immunohistochemical data show a different pattern of expression between normally healing and fibrotic wounds (exuberant granulation tissue and keloids), thus suggesting a role in fibroproliferation in horses and man.


Subject(s)
Gene Expression Regulation/physiology , Horses/metabolism , Keloid/metabolism , Osteopontin/metabolism , Wound Healing/physiology , Animals , Humans , Osteopontin/genetics , Polymerase Chain Reaction
3.
Curr Med Chem ; 16(6): 753-79, 2009.
Article in English | MEDLINE | ID: mdl-19199935

ABSTRACT

Protein therapeutics are playing an expanding role in modern medicinal chemistry. Among them, native or engineered molecules exploiting the binding and catalytic potential of the immune repertoire form an extremely exciting and emerging business area. They represent by far the single largest category of biopharmaceutical substances under investigation. The fast increase of this pharmaceutical category paralleled the scientific and technical progress from murine to chimeric, humanized and, finally, human engineered antibodies. Indeed, the development of the phage display technology, allowing libraries of shuffled murine or human antibody binding domains to be screened for affinity against a selected target antigen or activity against a specific reaction substrate, open new perspectives, disclosing the opportunity to circumvent restrictions inherent to the in vivo immunisation. Transgenic technology represents another powerful method for generating fully human monoclonal antibodies against a wide variety of drug targets, while recombinant technology continues to evolve, improving the pharmacodynamic and pharmacokinetic properties of antibody therapeutics, with the production of different antibody constructs or formats, such as bispecific antibodies, diabodies and others, and different functional activities, such as catalysis, cellular internalisation and antigen-mimicking. The aim of the present review is to overview native or recombinant antibodies while discussing the underlying antibody technology, with the aim to favour understanding of the antibody therapeutics that are in use or will enter market in the near future.


Subject(s)
Antibodies/therapeutic use , Biotechnology/methods , Antibodies/chemistry , Antibodies/immunology , Antibodies, Monoclonal/chemistry , Antibodies, Monoclonal/genetics , Antibodies, Monoclonal/therapeutic use , Humans
4.
J Parasitol ; 94(6): 1435-6, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18576861

ABSTRACT

Soboliphyme baturini, a stomach-dwelling nematode of American martens (Martes Americana), reaches high levels of infection; however, its effects on the nutritional condition of the host are unknown. To understand the effects of this parasite on American martens, we collected S. baturini and measured abdominal fat deposits from 155 marten carcasses on Prince of Wales Island, southeastern Alaska, in the winter 2006-2007. We analyzed how the dried mass of abdominal fat varied as a function of S. baturini intensity. Parasite intensity and nutritional condition were not correlated; these results suggest that American martens were able to withstand even very high levels of S. baturini infection (up to 178 parasites per host).


Subject(s)
Dioctophymatoidea/physiology , Enoplida Infections/veterinary , Mustelidae/parasitology , Nutritional Status , Stomach Diseases/veterinary , Age Distribution , Alaska/epidemiology , Animals , Enoplida Infections/epidemiology , Enoplida Infections/physiopathology , Female , Intra-Abdominal Fat/pathology , Male , Mesentery , Omentum , Prevalence , Sex Distribution , Stomach/parasitology , Stomach Diseases/epidemiology , Stomach Diseases/parasitology , Stomach Diseases/physiopathology
5.
Parasitol Res ; 102(5): 957-62, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18193281

ABSTRACT

In this study, some in vitro trials were carried out to evaluate the association between Scopulariopsis spp. fungi with Psoroptes cuniculi (Acari: Psoroptidae) and their potential pathogenicity to this mite species. After cultivation on Sabouraud dextrose agar with chloroamphenicol at 26 degrees C for 20 days and macro- and microscopical examinations, from P. cuniculi mites taken from some infested rabbits fungi belonging to the genus Scopulariopsis were isolated. Investigations were carried out to evaluate in vitro the potential pathogenic role of Scopulariopsis to P. cuniculi; to this aim, Scopulariopsis brevicaulis isolated from a cat was tested. In several culture media, the dose-dependent P. cuniculi mortality with different concentrations of S. brevicaulis and the ability of S. brevicaulis to penetrate inside the body of infected mites were evaluated. Results obtained demonstrated that, in the rabbit, Scopulariopsis fungi can be associated with P. cuniculi, and that S. brevicaulis can be an entomopathogen for P. cuniculi in a dose-dependent manner. A more rapid mortality of the mites and a quicker S. brevicaulis growth in plates containing rabbit serum with respect to all other media used were also found. S. brevicaulis demonstrated the ability to invade the body of P. cuniculi.


Subject(s)
Ascomycota/isolation & purification , Ascomycota/pathogenicity , Psoroptidae/microbiology , Rabbits/parasitology , Animals , Ascomycota/classification , Ascomycota/growth & development , Mite Infestations/parasitology , Mite Infestations/veterinary , Psoroptidae/physiology , Species Specificity , Virulence
6.
Clin Nephrol ; 67(3): 131-9, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17390737

ABSTRACT

BACKGROUND: The intact parathyroid hormone (PTH) serum value has been the non-invasive biomarker of choice for the early diagnosis of renal bone disease in the chronic kidney disease (CKD) patient population. It has now been known that the intact PTH assay value is the sum of 1-84 PTH (true hypercalcemic PTH) and large C-terminal PTH fragments, mainly 7-84 PTH, a fragment with hypocalcemic hormone actions. AIM: The aim of this study was to investigate the differences among the different functional stages of CKD in the following PTH parameters: intact PTH, 1-84 PTH, 7-84 PTH, and the ratio 1-84 PTH/7-84 PTH. GFR (clearance of 99mTc-DTPA) was measured in 164 (85 males and 79 females) adult CKD patients with different degrees of renal function impairment (serum creatinine 0.50 12.1 mg/dl, mean 2.00). PATIENTS AND METHODS: Plasma concentrations of calcium, phosphate, 1-84 PTH and intact PTH were also measured. The value of 7-84 PTH was calculated as the difference between intact PTH and 1-84 PTH. The reduction of, GFR was accompanied by an increase of intact PTH, with a prevalent increase of 7-84 PTH over 1-84 PTH, resulting in a decrease of the ratio 1-84 PTH/7-84 PTH. RESULTS: The values of 7-84 PTH showed a discrimination between Stages 1 and 2 (GFR > 60 ml/min ) and Stage 3 (GFR 30 60 ml/ min) CKD patient populations. In fact, 7-84 PTH was already significantly increased in patients at CKD Stage 3. The analysis of individual patients indicated that a low value (< 1.4) of the ratio 1-84 PTH/7-84 PTH, suggestive for low bone turnover, was already found in more than 20% of CKD Stage 3 patients. CONCLUSION: The results of the present study demonstrate that the reduction in GFR is accompanied by a higher increase in 7-84 PTH with respect to 1-84 PTH, which suggests the possibility that bone metabolism and calcemic status are already reduced in patients with moderate renal failure (CKD Stage 3).


Subject(s)
Glomerular Filtration Rate/physiology , Kidney Failure, Chronic/blood , Parathyroid Hormone/blood , Peptide Fragments/blood , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Calcium/blood , Disease Progression , Female , Humans , Kidney Failure, Chronic/diagnostic imaging , Kidney Failure, Chronic/physiopathology , Male , Middle Aged , Phosphates/blood , Prognosis , Radionuclide Imaging , Radiopharmaceuticals/pharmacokinetics , Severity of Illness Index , Technetium Tc 99m Pentetate/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...